Skip to main content

Header Image

We're here to serve our community. Find where to get your COVID-19 vaccine today through UT Physicians.

Read More from the Front Lines of COVID-19

Researchers from UTHealth Houston and other institutions conducted a multi-site, randomized, double-blind, placebo-controlled, adaptive Phase 2 trial evaluating the safety and efficacy of OP-101 in patients with severe COVID-19. (Photo by Getty Images)

Anti-inflammatory compound shows potential in treating patients with severe COVID-19

July 20, 2022 | Caitie Barkley

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chances of death, according to a new study from UTHealth Houston and other institutions.

Amber Luong, MD, PhD, conducted a retrospective cohort study to identify differences in inpatient otolaryngology consultations and interventions based on patients’ COVID-19 status. (Photo by UTHealth Houston)

Inpatient Otolaryngology Consults in the COVID-19 Era

July 15, 2022 | Karen Kephart

During consultations with head and neck surgeons, a significantly higher proportion of patients who tested positive for COVID-19 were treated for nosebleeds compared to patients who tested negative for the virus, according to researchers at UTHealth Houston. 

The trial revealed no difference in the risk of intubation requirement at 30 days between awake prone positioning and standard positioning for patients with COVID-19. (Photo by Getty Images)

Awake prone positioning does not offer benefit in reducing intubation for COVID-19 induced acute respiratory failure

June 28, 2022 | Halle Jones

A large multicenter, randomized clinical trial revealed no difference in the risk of endotracheal intubation requirement at 30 days between awake prone positioning and standard positioning for patients with COVID-19 who suffered from acute hypoxemic respiratory failure, according to research published in JAMA by researchers at UTHealth Houston.

Photo of woman getting her blood drawn. (Photo by Getty Images)

COVID-19 antibodies can last up to 500 days after infection

May 31, 2022 | Jeannette Sanchez

Adults infected with COVID-19 develop circulating antibodies that last for nearly 500 days, according to a new study led by researchers at UTHealth School of Public Health.

The findings were published in The Journal of Infectious Diseases.


Here for Our Community

UTHealth is committed to serving our community through education, research, and patient care. Working together, we will help each other, and our fellow citizens, through this pandemic.

UT Physicians

Visit with a primary or specialty care provider at one of our many locations or from the comfort of your home through our telehealth platform. Our clinics are open with expanded safety measures and ready to provide you with exceptional patient care. Telehealth visits are also available for any non-emergency and urgent care need.

Schedule your telehealth appointment:

Schedule an appointment at one of our many locations:

UTHealth Team Designs Face Shields for COVID-19 Response

With cake collar material, a three-hole punch, a scrapbooking paper trimmer, and the drive to protect those on the front lines of health care, a team from The University of Texas Health Science Center at Houston (UTHealth) has designed a face shield that can be used by thousands of providers in the Texas Medical Center.